RA Capital Management Sells Shares of Werewolf Therapeutics

RA Capital Management sold 128,770 shares of Werewolf Therapeutics, Inc. (NasdaqGS: HOWL) on June 15, 2026. The transaction, valued at $50,220, was executed at an average price of $0.39 per share.

What Changed in RA Capital Management's Werewolf Therapeutics Position

RA Capital Management reduced its holdings in Werewolf Therapeutics by 128,770 shares. This transaction was not part of a pre-planned trading program and reflects a direct sale of shares.

Other Institutional Activity in Werewolf Therapeutics

Vanguard Capital Management LLC added 1,217,976 shares to its holdings, ending with 1,217,976 shares valued at about $1,014,574. MPM Bioimpact LLC reduced its position by 184,747 shares, leaving it with 1,208,810 shares worth approximately $1,006,455. Meanwhile, Lynx1 Capital Management LP increased its stake by 1,860 shares to a total of 657,786 shares, valued at $547,673.

Werewolf Therapeutics, Inc. Stock Down 61.8%

Shares of Werewolf Therapeutics (NasdaqGS: HOWL) traded around $0.36 recently. The company has a market cap of about $17.5 million. Werewolf Therapeutics isn't profitable, so it doesn't have a meaningful forward P/E ratio. The stock has seen a 52-week low of $0.35 and a high of $2.38, with a 50-day moving average of $0.63 and a 200-day moving average of $0.95. The company has a current ratio of 1.27 and a quick ratio of 1.21, with a debt-to-equity ratio of 72.28.

Recent Earnings

Werewolf Therapeutics has been facing challenges with earnings, reporting a negative EPS of $1.21. The company has no net margin and a return on equity of -161.89%. Investors are looking forward to the next earnings report scheduled for August 13, 2026.

Insider Buying and Selling at Werewolf Therapeutics, Inc.

RA Capital Management has been actively trading shares of Werewolf Therapeutics. On June 16, 2026, they sold 149,625 shares at an average price of $0.37. Earlier, on June 12, they sold 170,441 shares at $0.40, and on June 11, they sold 262,503 shares at $0.38.

Analysts Set New Price Targets

Analysts remain optimistic about Werewolf Therapeutics. On December 19, 2025, HC Wainwright & Co. maintained a 'buy' rating with a price target of $4.00. Overall, the consensus among analysts is positive, with a mean target price of $4.00 based on one analyst opinion.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc. is a biotechnology company based in Watertown, Massachusetts. It focuses on developing innovative therapies that harness the body's immune system to fight cancer and other immune-related conditions. The company uses its proprietary PREDATOR platform to create conditionally activated molecules. These molecules are designed to stimulate adaptive and innate immunity, offering new treatments for solid tumors and lymphoma. Werewolf Therapeutics was founded in 2017 and employs 39 people.

Bottom Line

RA Capital Management's recent sale of Werewolf Therapeutics shares indicates a shift in its investment strategy. Investors will be watching closely for the company's next earnings report in August. Werewolf Therapeutics continues to attract interest from analysts, who see potential in its innovative approach to cancer treatment. As always, these reports reflect past transactions and may not represent current positions.